Abeona Therapeutics Independent Director Mark Alvino Sells 41% Of Holding
Abeona Therapeutics Independent Director Mark Alvino Sells 41% Of Holding
We'd be surprised if Abeona Therapeutics Inc. (NASDAQ:ABEO) shareholders haven't noticed that the Independent Director, Mark Alvino, recently sold US$117k worth of stock at US$4.51 per share. That sale was 41% of their holding, so it does make us raise an eyebrow.
如果您是Abeona therapeutics（納斯達克ABEO）的股東，您就會驚訝地發現，獨立董事Mark Alvino最近以每股4.51美元的價格出售了價值117,000美元的股票。這次交易佔他們所持股份的41%，讓我們開始警惕。
The Last 12 Months Of Insider Transactions At Abeona Therapeutics
Abeona Therapeutics最近12個月內的內部交易情況
Notably, that recent sale by Mark Alvino is the biggest insider sale of Abeona Therapeutics shares that we've seen in the last year. That means that even when the share price was slightly below the current price of US$4.58, an insider wanted to cash in some shares. We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. We note that the biggest single sale was only 41% of Mark Alvino's holding.
值得注意的是，Mark Alvino最近的交易是Abeona Therapeutics股票中我們在去年看到的最大的內部交易之一。這意味着即使股價略低於當前價格4.58美元，內部人士仍想套現一些股票。如果內部人士以低於當前價格出售，我們通常認爲是負面的，因爲這意味着他們認爲更低的價格是合理的。請注意，賣方可能有各種各樣的原因出售股票，所以我們不能確定他們對股票價格的看法。我們注意到最大的單筆交易僅佔Mark Alvino所持股份的41%。
In the last twelve months insiders purchased 88.76k shares for US$346k. But they sold 92.85k shares for US$411k. In total, Abeona Therapeutics insiders sold more than they bought over the last year. The average sell price was around US$4.43. We don't gain confidence from insider selling below the recent share price. Of course, the sales could be motivated for a multitude of reasons, so we shouldn't jump to conclusions. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去12個月中，內部人士購買了88.76k股，價值346,000美元。但他們賣出了92.85k股，價值411,000美元。總的來說，Abeona therapeutics內部人士賣出的股票比買入的股票還要多。平均賣出價格約爲4.43美元。內部人士低於最近的股票價格賣出不會增強我們的信心。當然，這些銷售可能是出於許多原因的動機，所以我們不應該做出任何結論。下面是過去12個月（按公司和個人）內部交易的可視化描述，如果您想知道誰以多少價格在什麼時候賣出，請單擊下面的圖表！
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜歡購買內部人員正在購買而不是銷售的股票，那麼你可能會喜歡這份免費的公司列表。（提示：它們中的大部分都被忽視了。）
Insider Ownership Of Abeona Therapeutics
Abeona therapeutics股權內部情況
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 3.2% of Abeona Therapeutics shares, worth about US$6.0m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.
對於普通股東來說，了解公司內部人士持有的股票數量是值得的。高比例的內部人士持有通常會使公司領導更加關注股東的利益。根據我們的數據，內部人士擁有Abeona therapeutics的3.2%股份，價值約600萬美元。雖然這比沒有強，但我們對這些持股並不是很印象深刻。
So What Do The Abeona Therapeutics Insider Transactions Indicate?
Abeona therapeutics內部交易的意義是什麼？
The stark truth for Abeona Therapeutics is that there has been more insider selling than insider buying in the last three months. And our longer term analysis of insider transactions didn't bring confidence, either. When you combine this with the relatively low insider ownership, we are very cautious about the stock. So we'd only buy after very careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Abeona Therapeutics. Every company has risks, and we've spotted 6 warning signs for Abeona Therapeutics (of which 3 are significant!) you should know about.
對於Abeona therapeutics來說，在過去三個月內，內部賣出的數量已超過內部買入的數量。我們對內部交易的長期分析也沒有帶來信心。當您將此與相對較低的內部所有權相結合時，我們對股票非常謹慎。因此，我們只會在非常仔細地考慮之後進行購買。除了了解正在進行的內部交易外，確定Abeona therapeutics可能面臨的風險也很有益。每家公司都有風險，我們已經在Abeona therapeutics（其中3個是重要的！）中發現了6個警告信號，您應該了解。
But note: Abeona Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
請注意：Abeona therapeutics可能不是最佳的購買股票。因此，請查看此具有高roe和低債務的有趣公司的免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。